Quanterix And Illumina Founder To Present Novel Approach To Cancer Diagnostics At Powering Precision Health 2016
Lexington, Mass. – Quanterix Corporation, a company digitizing biomarker analysis to accurately measure change for precision health, today announced it’s the official platinum co-sponsor of Powering Precision Health (PPH) 2016, the nation’s first summit dedicated to bringing the world’s leading physicians, scientists, innovators, investors and patient advocates together to unveil their latest research on new biomarkers that are revolutionizing precision health. Dr. David Walt, Scientific Founder of Quanterix and Founder of Illumina, will be presenting a keynote address at the summit focused on groundbreaking research in breast cancer diagnostics.
The inaugural summit will be held on the first day of Precision Health Awareness Week, September 26th, at the Boston Marriott Cambridge from 8:30 a.m. to 5:30 p.m. ET. Attracting some of the greatest minds in life sciences, including several Quanterix customers, the summit will spur discussions on scientific solutions based on novel research for preventing, detecting and treating disease long before symptoms are present. The tracks will be focused across a number of therapeutic categories, including oncology, neurology, cardiology, infectious disease and inflammation, with significant new findings and milestones being released in each to set the stage for disruption in today’s medical industry.
“Having been in life sciences for 25 years, I’ve been both inspired by disruptive technologies, and yet, frustrated when those innovations never see the light of day due to excessive regulations, lack of funding or entrenched mindsets,” said Kevin Hrusovsky, CEO and Executive Chairman, Quanterix. “We are passionate about the potential of PPH to help accelerate development of life-saving approaches in the fight against cancer, heart disease and neurodegenerative disorders and their underlying inflammation pathways. Quanterix precisely measures previously undetectable biomarkers, enabling a shift in healthcare focus to disease prevention, earlier detection, patient stratification and personalized drug development. We look forward to sharing groundbreaking research from our customers.”
Following recent recognition from NFL Commissioner Roger Goodell for the Company’s innovations in the neurology space, Quanterix customers will be leading the following scientific tracks at PPH, focused on their use of the company’s Simoa technology:
- Track 1 – Neurology:
- 1:30 – 2:00: Jessica Gill, PhD, RN, National Institute of Health: “The Role of Proteomic Biomarkers of Brain Injuries”
- 2:00 – 2:30: Danielle Graham, PhD, Biogen: “Accelerating Exploratory Fluid Biomarker Assay Development in Neurodegenerative Disease”
- 2:30 – 3:00: Alison Joyce, PhD, Pfizer Inc.: “Development of a Sensitive Homebrew Simoa Assay to Detect Leucine-Rich Repeat Kinase 2 (LRRK2)”
- 3:00 – 3:30: Cheryl Wellington, PhD, University of British Columbia: “Toward Precision Medicine in Canada: Two Vignettes”
- Track 2 – Oncology, Inflammation and Infectious Disease:
- 1:30 – 2:00: Ralph McDade, PhD, Myriad RBM: “Triphase Approach to Biomarker Pattern Discovery for Cancer Immunotherapy and Autoimmune Disease”
- 2:00 – 2:30: John Yan, Takeda Pharmaceutical Co: “An Ultrasensitive Assay Format for Detecting PD/Biomarkers in Cell and Xenograft Tumor”
- 2:30 – 3:00: Rama Boyanapalli, PhD, Shire Company: “The Long and Winding Road to a Highly Sensitive RANKL Assay”
- 3:00 – 3:30: Bonnie J. Howell PhD, Merck: “Ultrasensitive Detection of Viral p24 Following Reactivation of Latent HIV”
To learn more about the groundbreaking new research that will be presented at PPH, please register here: http://www.pphsummit.com/register.html.
Quanterix is a company that’s digitizing biomarker analysis to accurately measure change for precision health. The company’s digital health solution, Simoa, is changing the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. In doing so, Quanterix enables much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for applications in a majority of therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts.
Caitlyn Keating, 617-502-4300
Share this page